MedTrace Logo

Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines

NCT02385877 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-07-02

No results posted yet for this study

Summary

The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-\[18F\]fluoro-meta-hydroxyphenethylguanidine (\[18F\]4F-MHPG) and 3-\[18F\]fluoro-para-hydroxyphenethylguanidine (\[18F\]3F-PHPG).

Conditions

  • Autonomic Peripheral Nervous System Diseases

Interventions

DRUG

[18F]4F-MHPG

IV injection of \[18F\]4F-MHPG

DRUG

[18F]3F-PHPG

IV injection of \[18F\]3F-PHPG

Sponsors & Collaborators

Principal Investigators

  • David M Raffel, PhD · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02385877 on ClinicalTrials.gov